文献速递妇科

高通量筛选发现达沙替尼与曲美替尼在低级别浆液性卵巢癌中具有协同作用

High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
PubMed 文献 · Gynecol Oncol · 2024-04-05

本研究对6株低级别浆液性卵巢癌细胞系(3株RAS/RAF突变型、3株RAS/RAF野生型)进行1610种药物的高通量筛选,16种化合物被优先纳入验证,11种通过验证;达沙替尼等Src家族激酶抑制剂在多个低级别浆液性卵巢癌模型中与曲美替尼显示协同作用,双硫仑对低级别浆液性卵巢癌较高级别浆液性卵巢癌对照细胞系显示良好选择性。

要点

  • 1610种化合物高通量筛选后16种被优先验证,11种通过验证。
  • 双硫仑对低级别浆液性卵巢癌较高级别浆液性卵巢癌对照细胞系显示良好选择性(IC50比较P=0.003)。
  • 达沙替尼在多个低级别浆液性卵巢癌模型中与曲美替尼显示有利协同(最大零交互效力协同评分46.9)。

核心结论

  • 达沙替尼及其他Src家族激酶抑制剂是低级别浆液性卵巢癌的新型候选治疗药物,并与曲美替尼显示协同作用。
  • 双硫仑是另一种值得研究的治疗策略。

研究设计与样本

  • 对6株低级别浆液性卵巢癌细胞系(3株RAS/RAF突变型、3株RAS/RAF野生型)进行1610种药物的高通量筛选。
  • 验证包括在9个低级别浆液性卵巢癌模型和5株高级别浆液性卵巢癌对照细胞系中进行剂量-反应分析。

主要发现

  • 1610种筛选化合物中16种被优先纳入验证,标准为在1000 nM浓度下超过半数筛选细胞系中细胞核计数减少>50%。
  • 11种化合物通过验证,其中达沙替尼、双硫仑、卡非佐米和罗米地辛四种最受关注的药物与最近批准的MEK抑制剂曲美替尼进行了协同谱分析。
  • 双硫仑对低级别浆液性卵巢癌较高级别浆液性卵巢癌对照细胞系显示良好选择性(IC50比较P=0.003)。
  • 达沙替尼在多个低级别浆液性卵巢癌模型中与曲美替尼显示有利协同(最大零交互效力协同评分46.9)。
  • 新型高选择性Src家族激酶抑制剂NXP900与达沙替尼显示相似的曲美替尼协同谱,提示Src家族激酶抑制可能是协同作用的驱动因素。

关键数值与推荐

  • 优先验证标准:1000 nM浓度下超过半数筛选细胞系中细胞核计数减少>50%。
  • 双硫仑对低级别浆液性卵巢癌较高级别浆液性卵巢癌对照细胞系的选择性:IC50比较P=0.003。
  • 达沙替尼与曲美替尼在多个低级别浆液性卵巢癌模型中的最大零交互效力协同评分为46.9。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Low grade serous ovarian carcinoma (LGSOC) is a distinct histotype of ovarian cancer characterised high levels of intrinsic chemoresistance, highlighting the urgent need for new treatments. High throughput screening in clinically-informative cell-based models represents an attractive strategy for identifying candidate treatment options for prioritisation in clinical studies. METHODS: We performed a high throughput drug screen of 1610 agents across a panel of 6 LGSOC cell lines (3 RAS/RAF-mutant, 3 RAS/RAF-wildtype) to identify novel candidate therapeutic approaches. Validation comprised dose-response analysis across 9 LGSOC models and 5 high grade serous comparator lines. RESULTS: 16 hits of 1610 screened compounds were prioritised for validation based on >50% reduction in nuclei counts in over half of screened cell lines at 1000 nM concentration. 11 compounds passed validation, and the four agents of greatest interest (dasatinib, tyrosine kinase inhibitor; disulfiram, aldehyde dehydrogenase inhibitor; carfilzomib, proteasome inhibitor; romidepsin, histone deacetylase inhibitor) underwent synergy profiling with the recently approved MEK inhibitor trametinib. Disulfiram demonstrated excellent selectivity for LGSOC versus high grade serous ovarian carcinoma comparator lines (P = 0.003 for IC50 comparison), while the tyrosine kinase inhibitor dasatinib demonstrated favourable synergy with trametinib across multiple LGSOC models (maximum zero interaction potency synergy score 46.9). The novel, highly selective Src family kinase (SFK) inhibitor NXP900 demonstrated a similar trametinib synergy profile to dasatinib, suggesting that SFK inhibition is the likely driver of synergy. CONCLUSION: Dasatinib and other SFK inhibitors represent novel candidate treatments for LGSOC and demonstrate synergy with trametinib. Disulfiram represents an additional treatment strategy worthy of investigation.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Hollis RL, Elliott R, Dawson JC, et al. High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma. Gynecol Oncol. 2024. PMID: 38582027. doi:10.1016/j.ygyno.2024.03.029

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。